
Grifols, S.A. GRFS
$ 9.25
1.49%
Annual report 2024
added 01-24-2026
Grifols, S.A. DIO Ratio 2011-2026 | GRFS
Annual DIO Ratio Grifols, S.A.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | - | 0.000171 | 261 | 263 | 275 | 282 | - |
All numbers in EUR currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 282 | 0.000171 | 216 |
DIO Ratio of other stocks in the Biotechnology industry
| Issuer | DIO Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
GlaxoSmithKline plc
GSK
|
200 | $ 48.98 | 0.68 % | $ 173 B | ||
|
Acorda Therapeutics
ACOR
|
345 | - | -24.86 % | $ 820 K | ||
|
Aeterna Zentaris
AEZS
|
55.6 | - | 5.93 % | $ 314 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
512 | - | - | $ 40.3 B | ||
|
Amphastar Pharmaceuticals
AMPH
|
132 | $ 25.92 | -0.86 % | $ 1.26 B | ||
|
Midatech Pharma plc
MTP
|
40.6 | - | -18.52 % | $ 27.3 M | ||
|
Galapagos NV
GLPG
|
0.915 | $ 34.61 | 0.61 % | $ 2.69 B | ||
|
Ultragenyx Pharmaceutical
RARE
|
1.25 K | $ 24.45 | 4.49 % | $ 2.21 B | ||
|
Институт стволовых клеток человека
ISKJ
|
275 | - | - | - | ||
|
BioXcel Therapeutics
BTAI
|
227 | $ 1.84 | 1.66 % | $ 4.66 M | ||
|
Aytu BioScience
AYTU
|
209 | $ 2.66 | -1.85 % | $ 16.7 M | ||
|
Acasti Pharma
ACST
|
136 | - | 4.01 % | $ 150 M | ||
|
BeiGene, Ltd.
BGNE
|
304 | - | 0.49 % | $ 251 B | ||
|
Albireo Pharma
ALBO
|
26.1 | - | -0.23 % | $ 916 M | ||
|
Coherus BioSciences
CHRS
|
116 | $ 2.04 | 28.3 % | $ 192 M | ||
|
Biogen
BIIB
|
394 | $ 171.89 | -1.1 % | $ 25 B |